The combination does not have a single molecular formula or molecular weight because CJC-1295 and Ipamorelin remain separate chemical entities within the formulation. Their individual molecular specifications may vary depending on acetate, trifluoroacetate, hydrate, or other material forms. Researchers should verify the identity, component ratio, salt composition, and analytical specifications of both peptides through the Certificate of Analysis before performing molecular calculations or preparing experimental protocols.
Within controlled research environments, CJC-1295 + Ipamorelin may be investigated in experimental models involving GHRH receptor interactions, growth hormone secretagogue receptor (GHS-R1a) signaling, ligand-receptor recognition, intracellular signaling mechanisms, and comparative peptide characterization. These investigations may examine the individual and combined biochemical behavior of the two peptides under defined experimental conditions without assuming additive or synergistic effects.
Establish experimental parameters independently for each research protocol. Researchers should assess solvent compatibility, individual peptide concentrations, formulation ratios, pH, physicochemical stability, analytical methodology, temperature sensitivity, storage conditions, and potential interactions between formulation components before incorporating CJC-1295 + Ipamorelin into a controlled laboratory workflow.
Research Applications
CJC-1295 + Ipamorelin may support controlled laboratory studies involving:
- Growth hormone-releasing hormone (GHRH) receptor research
- Growth hormone secretagogue receptor (GHS-R1a) studies
- Peptide-receptor interaction analysis
- Molecular signaling pathway research
- Structure-activity relationship investigations
- Ligand-receptor binding characterization
- Combined peptide formulation studies
- Comparative biochemical research
- Analytical method development
- Peptide stability and degradation investigations
Storage and Handling
Store CJC-1295 + Ipamorelin according to the conditions specified on the product label, Certificate of Analysis, or accompanying technical documentation. Protect the material from excessive heat, moisture, direct light, and unnecessary environmental exposure. Storage requirements may differ depending on the individual peptide forms, formulation composition, and product-specific stability characteristics.
For lyophilized material, maintain the container securely sealed until required for controlled laboratory preparation. Once prepared in solution, stability may depend on solvent composition, peptide concentrations, pH, temperature, container compatibility, and storage duration. Researchers should evaluate the stability of both components independently and within the combined formulation using suitable analytical procedures.
Avoid repeated temperature fluctuations and unnecessary environmental exposure where possible. Follow appropriate laboratory handling procedures and maintain accurate records of preparation dates, storage conditions, component concentrations, formulation identification, lot numbers, and analytical use. Documented handling practices support consistency, material traceability, and reproducibility throughout experimental research.
Product Specifications
Product Name: CJC-1295 + Ipamorelin
Alternative Names: CJC-1295 (No DAC) + Ipamorelin, Modified GRF (1-29) + Ipamorelin, CJC-1295/Ipamorelin Blend
Product Category: Synthetic peptide combination
Peptide Components: CJC-1295 (No DAC) and Ipamorelin
CJC-1295 Peptide Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
Ipamorelin Peptide Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Peptide Length: CJC-1295 (No DAC): 29 amino acid residues; Ipamorelin: 5 amino acid residues
CAS Numbers: CJC-1295 (No DAC): 863288-34-0 (commonly referenced); Ipamorelin: 170851-70-4
Molecular Formula: CJC-1295 (No DAC): C₁₅₂H₂₅₂N₄₄O₄₂; Ipamorelin: C₃₈H₄₉N₉O₅
Molecular Weight: CJC-1295 (No DAC): Approximately 3367.9 g/mol; Ipamorelin: Approximately 711.9 g/mol
Structural Modification: CJC-1295 contains four amino acid substitutions without DAC modification; Ipamorelin contains non-natural amino acid residues and a C-terminal amide
Material Form: Verify through lot-specific documentation
Salt Form: Verify individual peptide salt forms through product-specific documentation
Appearance: May be supplied as a lyophilized peptide blend; confirm lot-specific documentation
Purity: Refer to lot-specific Certificate of Analysis for individual peptide purity
Component Ratio: Verify through product label and lot-specific analytical documentation
Container Type: Sealed research vial or product-specific container
Testing Documentation: Lot-specific analytical records, where provided
Intended Setting: Controlled laboratory research
Use Classification: Research use only
Human or Veterinary Use: Prohibited
Quality Assurance
Each lot of CJC-1295 + Ipamorelin should include appropriate product-specific documentation, where available. Analytical records may include identity confirmation for both peptide components, individual purity assessments, chromatographic analysis, mass-spectrometric characterization, molecular specifications, component content verification, batch identification, and recommended storage conditions. These records support the analytical characterization and traceability of the combined peptide material.
Researchers should verify that the stated peptide identities, molecular formulas, molecular weights, salt forms, individual purity values, component ratios, and lot numbers correspond with the Certificate of Analysis before beginning experimental work. Analytical documentation should distinguish CJC-1295 (No DAC) from DAC-modified CJC-1295 and identify Ipamorelin as a separate component. A reported combined purity value should not automatically be interpreted as confirmation of the individual purity or content of both peptides.
Because molecular specifications may differ between free peptides and their acetate, trifluoroacetate, or other salt forms, lot-specific documentation should serve as the primary reference for analytical calculations, material identification, formulation verification, and experimental recordkeeping. Appropriate testing and documentation help maintain consistency when evaluating individual peptide characteristics and combined formulation behavior under controlled laboratory conditions.
Research Use Disclaimer
For laboratory research use only. Not for human or veterinary use. Not intended for injection, administration, diagnosis, treatment, cure, or prevention of any disease. Do not use this research product as a food, drug, cosmetic, dietary supplement, or household product.
Formulation note: This description assumes CJC-1295 (No DAC) + Ipamorelin, consistent with your previous product. The DAC status and component ratio must be confirmed against your actual product label or COA before publication.




Reviews
There are no reviews yet.